[1] Popescu L M, Faussone-Pellegrini M S. TELOCYTES—a case of serendipity: the winding way from interstitial cells of Cajal (ICC), via interstitial Cajal-like cells (ICLC) to TELOCYTES [J]. Journal of Cellular Molecular Medicine, 2010, 14(4): 729-740.
[2] Faussone-Pellegrini M S, Popescu L M. Telocytes [J]. Biomolecular Concepts, 2011, 2(6): 2481-2489.
[3] Cretoiu S M, Popescu L M. Telocytes revisited [J]. Biomolecular Concepts, 2014, 5(5): 353-369.
[4] Cretoiu S M, Cretoiu D, Popescu L M. Human myometrium-the ultrastructural 3D network of telocytes [J]. Journal of Cellular Molecular Medicine, 2012, 16(11): 2844-2849.
[5] Xiao J,Wang F, Liu Z, Yang C. Telocytes in liver: electron microscopic and immunofluorescent evidence [J]. Journal of Cellular Molecular Medicine, 2013, 17(12): 1537-1542.
[6] Cretoiu D, Cretoiu S M, Simionescu A A, et al. Telocytes, a distinct type of cell among the stromal cells present in the lamina propria of jejunum [J]. Histology and Histopathology, 2012, 27(8): 1067-1078.
[7] Zheng Y, Li H, Manole C G, et al. Telocytes in trachea and lungs [J]. Journal of Cellular and Molecular Medicine, 2011, 15(10): 2262-2268.
[8] Popescu B O, Gherghiceanu M, Kostin S, et al. Telocytes in meninges and choroid plexus [J]. Neuroscience Letters, 2012, 516(2): 265-269.
[9] Vannucchi M G, Traini C, Manetti M, et al. Telocytes express PDGFRa in the human gastrointestinal tract [J]. Journal of Cellular and Molecular Medicine, 2013, 17(9): 1099-1108.
[10] Mou Y, Wang Y, Li J, et al. Immunohistochemical characterization and functional identification of mammary gland telocytes in the self-assembly of reconstituted breast cancer tissue in vitro [J]. Journal of Cellular and Molecular Medicine, 2013, 17(1): 65-75.
[11] Kostin S. Myocardial telocytes: a specific new cellular entity [J]. Journal of Cellular and Molecular Medicine, 2010, 14(7): 1917-1921.
[12] Cantarero I, Luesma M J, Junquera C. The primary cilium of telocytes in the vasculature: electron microscope imaging [J]. Journal of Cellular and Molecular Medicine, 2011, 15(12): 2594-2600.
[13] Gherghiceanu M, Popescu L M. Cardiomyocyte precursors and telocytes in epicardial stem cell niche: electron microscope images [J]. Journal of Cellular and Molecular Medicine, 2010, 14(4): 871-877.

[14] Popescu L M, Manole E, Serboiu C S, et al. Identification of telocytes in skeletal muscle interstitium: implication for muscle regeneration [J]. Journal of Cellular and Molecular Medicine, 2011, 15(6): 1379-1392.
[15] Chen X, Zheng Y, Manole C G, et al. Telocytes in human oesophagus [J]. Journal of Cellular and Molecular Medicine, 2013, 17(11): 1506-1512.
[16] Cretoiu D, Hummel E, Zimmerann H, et al. Human cardiac telocytes: 3D imaging by FIBSEM tomography [J]. Journal of Cellular and Molecular Medicine, 2014, 18(11): 2157-2164.
[17] Popescu L M, Fertig E T, Gherghiceanu M. Reaching out: junctions between cardiac telocytes and cardiac stem cells in culture [J]. Journal of Cellular Molecular Medicine, 2016, 20(2): 370-380.
[18] Liao Z F, Cai D Q. Cardiac telocytes in regeneration of myocardium after myocardial infarction [J]. Advances in Experimental Medicine and Biology, 2016, 913: 229-239.
[19] Manole C G, Cismagiu V, Gherghiceanu M, et al. Experimental acute myocardial infarction: telocytes involvement in neo-angiogenesis [J]. Journal of Cellular Molecular Medicine, 2011, 15(11): 2284-2296.
[20] Zhao B, Chen S, Liu J, et al. Cardiac telocytes were decreased during myocardial infarction and their therapeutic effects for ischaemic heart in rat [J]. Journal of Cellular and Molecular Medicine, 2013, 17(1): 123-133.
[21] Zhao B, Liao Z, Chen S, et al. Intramyocardial transplantation of cardiac telocytes decreases myocardial infarction and improves post-infarcted cardiac function in rats [J]. Journal of Cellular Molecular Medicine, 2014, 18(5): 780-789.
[22] Hong S J, Choi S C, Kim J S, et al. Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-month effects on coronary flow reserve and angiogenic cell
mobilisation [J]. Heart, 2010, 96(10): 756-764.
[23] Campeanu R A, Radu B M, Cretoiu S M, et al. Near-infrared low-level laser stimulation of telocytes from human myometrium [J]. Lasers in Medical Science, 2014, 29(6): 1867-1874.
[24] White H D, Norris R M, Brown M A, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction [J]. Circulation, 1987, 76(1): 44-51.
[25] Joyce E, Hoogslag G E, Leong D P, et al. Association between left ventricular global longitudinal strain and adverse left ventricular dilatation after ST-segment-elevation myocardial
infarction [J]. Circulation Cardiovascular Imaging, 2014, 7(1): 74-81.
[26] Cretoiu D, Radu B M, Banciu A, et al. Telocytes heterogeneity: from cellular morphology to functional evidence [J]. Seminars in Cell & Developmental Biology, 2017(64): 26-39.
[27] Schachinger V, Assmus B, Britten M B, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCAREAMI Trial [J]. Journal of American College of Cardiology, 2004, 44(8): 1690-1699.
[28] Fu S Y, Zhu H, Li S Y, et al.Telocytes in cardiac protection [J]. Current Stem Cell Research & Therapy, 2016, 11(5): 390-394.
[29] Xiao J, Chen P, Qu Y, et al. Telocytes in exercise-induced cardiac growth [J]. Journal of Cellular Moecular Medicine, 2016, 20(5): 973-979.

[30] Schulze H, Schepers U, Sandhoff K. Overexpression and mass spectrometry analysis of mature human acid ceramidase [J]. Biological Chemistry, 2007, 388(12): 1333-1343.
[31] Jia Y, Xu J, Yu Y, et al. Nifedipine inhibits angiotensinⅡ-induced cardiac fibrosis via downregulating Nox4-derived ROS generation and suppressing ERK1/2, JNK signaling pathways [J]. Pharmazie, 2013, 68(6): 435-441.
[32] Teng G Q, Svystonyuk D, Mewhort H E M, et al. Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis [J]. American Journal of Physiology: Heart
and Circulatory Physiology, 2015, 308(12): 1564-1574.
[33] Noppe G, Dufeys C, Buchlin P, et al. Reduced scar maturation and contractility lead to exaggerated left ventricular dilation after myocardial infarction in mice lacking AMPKa1 [J].
Journal of Molecular and Cellular Cardiology, 2014, 74: 32-43.
[34] Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples)Ⅱtrial: impact of a single high loading dose of atorvastatin on periprocedural
myocardial infarction [J]. Journal of the American College of Cardiology, 2009, 54(23): 2157-2163.
[35] Teshima Y, Yufu K, Akioka H, et al. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction [J]. Journal of Cardiology, 2009, 53(1): 58-64.
[36] Pedersen T R, Faergeman O, Kastelein J J P, et al. High-dose atorvastatin vs usualdose simvastatin for secondary prevention after myocardial infarction—the IDEAL study: a
randomized controlled trial [J]. JAMA, 2005, 294(19): 2437-2445.